7WN1 image
Entry Detail
PDB ID:
7WN1
EMDB ID:
Title:
Structure of PfNT1(Y190A) in complex with nanobody 48 and inosine
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2022-01-17
Release Date:
2023-02-01
Method Details:
Experimental Method:
Resolution:
3.11 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Equilibrative nucleoside/nucleobase transporter
Mutations:Y190A
Chain IDs:A
Chain Length:422
Number of Molecules:1
Biological Source:Plasmodium falciparum
Polymer Type:polypeptide(L)
Description:nanobody48
Chain IDs:B (auth: C)
Chain Length:122
Number of Molecules:1
Biological Source:Vicugna pacos
Ligand Molecules
Primary Citation
Structural basis of the substrate recognition and inhibition mechanism of Plasmodium falciparum nucleoside transporter PfENT1.
Nat Commun 14 1727 1727 (2023)
PMID: 36977719 DOI: 10.1038/s41467-023-37411-1

Abstact

By lacking de novo purine biosynthesis enzymes, Plasmodium falciparum requires purine nucleoside uptake from host cells. The indispensable nucleoside transporter ENT1 of P. falciparum facilitates nucleoside uptake in the asexual blood stage. Specific inhibitors of PfENT1 prevent the proliferation of P. falciparum at submicromolar concentrations. However, the substrate recognition and inhibitory mechanism of PfENT1 are still elusive. Here, we report cryo-EM structures of PfENT1 in apo, inosine-bound, and inhibitor-bound states. Together with in vitro binding and uptake assays, we identify that inosine is the primary substrate of PfENT1 and that the inosine-binding site is located in the central cavity of PfENT1. The endofacial inhibitor GSK4 occupies the orthosteric site of PfENT1 and explores the allosteric site to block the conformational change of PfENT1. Furthermore, we propose a general "rocker switch" alternating access cycle for ENT transporters. Understanding the substrate recognition and inhibitory mechanisms of PfENT1 will greatly facilitate future efforts in the rational design of antimalarial drugs.

Legend

Protein

Chemical

Disease

Primary Citation of related structures